Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: Lu AG09222 for Migraine Prevention
NCT05133323Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- IgG Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of lu ag09222 in migraine, sponsored by Lundbeck. Started Nov 2021; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05133323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133323.